Charles Rhyee, an analyst from TD Cowen, maintained the Buy rating on IQVIA Holdings. The associated price target was raised to $213.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Charles Rhyee has given his Buy rating due to a combination of factors tied to IQVIA’s revised business structure and stable outlook. He highlights that the company’s new two-segment setup—Research & Development Solutions, now incorporating Real-World Evidence, and Commercial Solutions, encompassing the remaining legacy units—better reflects how the business actually operates and creates value.
At the same time, he keeps his financial projections unchanged, indicating that the revised reporting format does not alter his fundamental view of IQVIA’s earnings power or growth trajectory. This consistency in estimates, alongside improved transparency from the new segmentation, supports his conviction that the stock remains attractively positioned for investors at current levels, justifying a continued Buy recommendation.
In another report released on March 21, TipRanks – PerPlexity also upgraded the stock to a Buy with a $192.00 price target.